(NASDAQ:TENX), Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or […]
(NYSE:COHR), FY25 REVENUE OF $5.81B, INCREASED 23% Y/Y FY25 GAAP GROSS MARGIN OF 35.2%, INCREASED 424 bps Y/Y; FY25 NON-GAAP GROSS MARGIN OF 37.9%, INCREASED 358 bps Y/Y FY25 GAAP LOSS OF $0.52, IMPROVED $1.32 Y/Y; FY25 NON-GAAP EPS OF $3.53, IMPROVED $2.32 Y/Y SAXONBURG, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE:
(NASDAQ:BIVI), CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia
(NASDAQ:NDLS), BROOMFIELD, Colo., Aug. 13, 2025 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 1, 2025. Key highlights for the second quarter of 2025 versus the second quarter of 2024 include: Total revenue decreased 0.7% to $126.4 million from $127.4 million in the second quarter
(NASDAQ:HTCR), NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 and Recent Operational & Financial Highlights As
(NasdaqGM:RDZN), 1. Record Fiscal Q1 Revenue Sets Stage for the Year AheadFirst quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last year – the strongest first quarter revenue on record for Roadzen, driven by growth in India and the U.S., along with the resumption of U.K. business opportunities. 2. Significantly Narrowed
(NasdaqGM:IMRX), – Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance – – Exceptional 94% overall survival (OS) observed at 6 months in ongoing Phase 2a trial of atebimetinib plus modified Gemcitabine/nab-paclitaxel (mGnP) in
(NASDAQ:ALLO), Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion vs. Observation More than 50 sites Activated Across the U.S. and Canada, with Additional International Expansion Underway; Scheduled Futility
(NASDAQ:CDXS), Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis(R) platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS),
(NASDAQ:XPON), Q2 2025 Sales Growth of 134% to $3.0 Million Fueled by Strong Demand for New Products and Technologies Records Two of the Most Successful Months of Sales in Company History in Q2 2025 Sixth Consecutive Quarter of Sales Growth REDMOND, Ore., Aug. 13, 2025 (GLOBE NEWSWIRE) — Expion360 Inc. (Nasdaq: XPON) (“Expion360” or the